



Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Failures

Recommended and alternative regimens listed by evidence level and alphabetically for:

Sofosbuvir-Based Treatment Failures, With or Without Compensated Cirrhosis^a

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) ^b	12 weeks	I, A
ALTERNATIVE	DURATION	RATING 
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) except for NS3/4 protease inhibitor inclusive combination DAA regimen failures ^c <ul style="list-style-type: none"> • Not recommended for genotype 3 infection with sofosbuvir/NS5A inhibitor experience. 	16 weeks	I, A


^a For [decompensated cirrhosis](#), please refer to the appropriate section.
^b Genotype 3: Add weight-based ribavirin if cirrhosis is present and there are no contraindications.
^c This regimen is not recommended for patients with prior exposure to an NS5A inhibitor plus NS3/4 PI regimens (eg. Elbasvir/grazoprevir).

Last update: January 21, 2021

Glecaprevir/Pibrentasvir Treatment Failures

Recommended regimens listed by evidence level and alphabetically for:

Glecaprevir/Pibrentasvir Treatment Failures (All Genotypes), With or Without Compensated Cirrhosis^a

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) plus daily sofosbuvir (400 mg) and weight-based ribavirin	16 weeks	IIa, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)	12 weeks	IIa, B

Recommended regimens listed by evidence level and alphabetically for:

Glecaprevir/Pibrentasvir Treatment Failures (All Genotypes), With or Without Compensated Cirrhosis^a

For patients with compensated cirrhosis, addition of weight-based ribavirin is recommended.	12 weeks	Ila, C
---	----------	--------

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

Last update: January 21, 2021

Multiple DAA Treatment Failures (All Genotypes), Including Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir Plus Glecaprevir/Pibrentasvir

Recommended regimens listed by evidence level and alphabetically for:

Sofosbuvir/Velpatasvir/Voxilaprevir Treatment Failures, With or Without Compensated Cirrhosis^a

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) plus daily sofosbuvir (400 mg) and weight-based ribavirin	16 weeks ^b	Ila, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) plus weight-based ribavirin	24 weeks	Ila, B

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b Extension of treatment to 24 weeks should be considered in extremely difficult cases (eg, genotype 3 with cirrhosis) or failure following sofosbuvir plus glecaprevir/pibrentasvir.

Last update: January 21, 2021